Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1-2 Study of Onapristone in Patients With Progesterone Receptor Expressing Cancers

Trial Profile

Phase 1-2 Study of Onapristone in Patients With Progesterone Receptor Expressing Cancers

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 31 May 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Onapristone (Primary) ; Onapristone (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Endometrial cancer; Ovarian cancer; Solid tumours; Uterine cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Arno Therapeutics
  • Most Recent Events

    • 31 May 2019 Results of pooled analysis of this and NCT02049190 assessing safety of onapristone in patients with metastatic cancer, published in conjunction with 55th Annual Meeting of the American Society of Clinical Oncology (2019).
    • 07 Jun 2016 Results from this trial and other trial (NCT02049190) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 02 Jun 2015 Results of immunohistochemical biomarker analysis and clinical benefit in phase I cohorts presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top